Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1Gaucher Disease 1

Interventions

pembrolizumab 410Cyclophosphamide 399Carboplatin 307Gemcitabine 287Nivolumab 276Paclitaxel 274Cisplatin 253Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 196Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × ganglioside, GD2 × Clear all
NCT04637503 2020-11-19

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma

Shenzhen Geno-Immune Medical Institute

Phase 1/2 Unknown
100 enrolled
CNS

Gaucher Disease, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡